Microsoft word - novelos-pr-$2mil-pipe-11-5-12

NOVELOS THERAPEUTICS CLOSES $2 MILLION PRIVATE PLACEMENT
Initiates Build-out of Manufacturing Facility for I-124-CLR1404 (LIGHT)
MADISON, Wisc. (November 5, 2012) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a
pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today
announced the closing of a private placement of equity securities to an affiliated entity of Renova
Group for gross proceeds to Novelos of $2 million. The securities issued and sold in the private
placement consisted of 2 million shares of Novelos’ common stock, a warrant to purchase up to 1
million shares of common stock at an exercise price of $1.25 per share expiring in five years and
a warrant to purchase up to 2 million shares of common stock at an exercise price of $1.00 per
share expiring in 90 days. Novelos has earmarked the proceeds for the build-out of an in-house
clinical-stage manufacturing facility for I-124-CLR1404 (LIGHT), our small-molecule, broad-
spectrum, cancer-targeted imaging agent. The facility is expected to be completed in about one
year and is expected to cost approximately $3 million.
“We are very pleased to have a multi-billion dollar institutional investor of Renova’s stature join
our existing institutional and retail investors,” said Harry Palmin, President and CEO of Novelos.
“Having demonstrated initial positive LIGHT imaging data in lung and brain cancer patients and
awaiting initial LIGHT imaging data across nine other solid tumor indications starting early next
year, the build-out of an in-house clinical-stage manufacturing facility for LIGHT is a key
strategic initiative as we move toward larger Phase 2 and pivotal LIGHT imaging trials. In the
interim, we believe additional positive data will further establish proof-of-concept for LIGHT as a
PET imaging agent in multiple cancer indications as well as guide selection of indications and
trial designs for Phase 2 clinical trials with I-131-CLR1404 (HOT). We already have an
operational in-house clinical-stage manufacturing facility for HOT, our small-molecule, broad-
spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and
selectively to cancer cells and cancer stem cells.”
About Renova Group
Renova Group is a leading Russian private business group that holds and manages assets in
metallurgy, oil, mining, chemical, real estate development, energy, telecommunications, high-
tech engineering, transport industry, utilities and financial sectors in Russia as well as CIS,
Switzerland, Italy, South Africa and the United States. Among the Group’s most important
inputs are investments in TNK-BP, UC RUSAL, IES, as well as in Swiss high-tech and industrial
companies OC Oerlikon and Sulzer. For additional information please visit
www.renova.ru/en/about/
About LIGHT
LIGHT is a small-molecule, broad-spectrum, cancer-targeted imaging agent that we believe has
first-in-class potential for selective detection of tumors and metastases in a broad range of
cancers. LIGHT is comprised of a proprietary phospholipid ether analog (PLE), acting as a
cancer-targeted delivery and retention vehicle, covalently labeled with iodine-124, a short-lived
PET imaging radioisotope. PET imaging used in conjunction with CT scanning has now become
the imaging method of choice in oncology. In studies to date, LIGHT selectively illuminated
malignant tumors in 52 of 54 animal models of cancer, demonstrating broad-spectrum, cancer-

selective uptake and retention. Investigator-sponsored Phase 1-2 trials of LIGHT as a PET
imaging agent are ongoing across 11 solid tumor indications. Initial positive imaging results have
been established in patients with lung and brain cancers. These human trials, if successful, would
likely provide proof-of-concept for LIGHT as a PET imaging agent with the potential to supplant
the current “gold standard” agent, 18F-fluoro-deoxyglucose (FDG), due to what we believe to be
LIGHT’s superior cancer-specificity and more favorable logistics of clinical use. As a chemically
identical biomarker for HOT, we believe that LIGHT tumor uptake data could accelerate clinical
development of HOT by guiding selection of indications for HOT Phase 2 trials and potentially
be used in such trials to identify suitable patients and assess therapeutic efficacy. For the same
reason, and in view of the quantitative nature of PET imaging, we also believe that LIGHT
imaging may be capable of estimating an efficacious dose of HOT in individual patients.

About Novelos Therapeutics, Inc.
We are a pharmaceutical company developing novel drugs for the treatment and diagnosis of
cancer. Our cancer-targeted compounds are selectively taken up and retained in cancer cells,
including cancer stem cells, versus normal cells. Thus, our therapeutic compounds appear to
directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a
paradigm shift in cancer therapy by providing efficacy versus all three major drivers of mortality
in cancer: primary tumors, metastases and stem cell-based relapse. I-124-CLR1404 (LIGHT) is a
small-molecule, broad-spectrum, cancer-targeted PET imaging agent. We believe LIGHT has
first-in-class potential and Phase 1-2 clinical trials are ongoing across 11 solid tumor indications.
I-131-CLR1404 (HOT) is a small-molecule, broad-spectrum, cancer-targeted molecular
radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and
cancer stem cells. We believe HOT also has first-in-class potential. HOT Phase 1b dose-
escalation trial is ongoing and, subject to additional funding, we expect HOT to enter Phase 2
trials in the third quarter of 2013 as a monotherapy for solid tumors with significant unmet
medical need. CLR1502 (GLOW2) is a preclinical, cancer-targeted, non-radioactive optical
imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.
Together, we believe our compounds are able to “find, treat and follow” cancer anywhere in the
body in a novel, effective and highly selective way. For additional information please visit
www.novelos.com

INVESTOR CONTACTS
J. Patrick Genn, Vice President of IR, Novelos Therapeutics, Inc., Madison, Wisc. & Boston,
Mass., Ph: (858) 775-7456, Email: jpgenn@novelos.com
Anne Marie Fields, Senior Vice President, LHA, Ph: (212) 838-3777, Email: afields@lhai.com,
@LHA_IR_PR
This news release contains forward-looking statements. You can identify these statements by our
use of words such as “may,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,”
“continue,” “plans,” or their negatives or cognates. Such statements are valid only as of today,
and we disclaim any obligation to update this information. These statements are only estimates
and predictions and are subject to known and unknown risks and uncertainties that may cause
actual future experience and results to differ materially from the statements made. These
statements are based on our current beliefs and expectations as to such future outcomes. Drug
discovery and development involve a high degree of risk. Factors that might cause such a
material difference include, among others, uncertainties related to the ability to attract and retain
partners for our technologies, the identification of lead compounds, the successful preclinical
development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators’ ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.

Source: http://cellectar2014.mhwebstaging.com/wp-content/uploads/2014/02/Novelos-PR-2mil-PIPE-11-5-12.pdf